SP-0196: A practical guide to radiochromic film dosimetry  by Stock, M.
S76  2nd ESTRO Forum 2013	
 TEACHING LECTURE:  
  
SP-0192   
Biomarkers and the prediction of outcome in breast conserving 
therapy 
H. Bartelink1 
1The Netherlands Cancer Institute - Antoni van Leeuwenhoek 
Hospital, Department of Radiation Oncology, Amsterdam, The 
Netherlands  
  
Risk factors for local recurrence in breast cancer after breast 
conserving therapy (BCT) differ from those for local recurrence after 
mastectomy. To better guide optimal treatment of individual 
patients, it is desirable to identify patients at high risk for local 
recurrence. Several clinical and histopathological factors, such as 
young age and presence of ductal carcinoma in situ, are known to be 
predictors for local recurrence after BCT. After mastectomy lymph 
node status and tumor size are dominant risk factors for local 
recurrence. Extensive research was therefore aimed at developing and 
validating biomarkers to predict a local recurrence after BCT. 
Recent gene expression profiling studies are already in clinical use for 
predicting prognosis and guiding the indication for adjuvant systemic 
therapy and in some cases also the type of chemotherapy. 
New published and unpublished data reveal that these and other gene 
expression profiles may be used to predict local recurrence after BCT 
or RM. Although the variation in different subtypes in breast cancer 
and the difference in amount of tumor burden remaining after 
surgery, makes that finding robust predictive profiles is still complex.  
During this teaching lecture biomarkers will be presented for 
predicting local recurrence after mastectomy and BCT, and they also 
will be related to the outcome of some recent clinical trials. 
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MRI for radiotherapy planning 
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High dose radiation therapy requires accurate localization of the 
tumor volume and its relationship to surrounding normal tissue. 
Further parameters that influence the results of radiation therapy are 
mainly related to tumor characteristics and the radiation technique 
used. 
As compared to CT, radiotherapy planning with MRI has major 
advantages. Tumor delination by MRI is improved due to its superior 
soft tissue contrast. Furthermore, functional data such as the 
oxygenisation status, pH, and the tissue temperature of the tumor can 
be obtained. In addition MRI does not use ionizing radiation. 
Therefore, MRI maybe optimal for radiotherapy planning. 
However, because of difficulties in image interpretation and image 
distortion as well as missing radiation absorption information it is 
currently not used routinetly. Therefore CT is still used more 
frequently. Thus methods are being developed to convert MRI tissue 
intensities into HU data surrogates for radiation planning. 
Using new fast pulse sequences and standard plastic radiation therapy 
immobilization casts with  MR positive surface markers, MRI may be 
employed more frequently. Areas in which MRI is already used are 
those areas of the body with low or almost no movement such as the 
brain, head and neck-region, and pelvic organs, such as the uterus and 
prostate.  
During the last years positron emission tomography (PET) is of growing 
importance for radiotherapy planning. Since first combined MR-PET-
systems are available MR imaging may play a major role in the future 
of  radiotherapy planning. 
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Functional MRI: how can it assist IMRT 
R. Beets-Tan1 
1Maastricht Radiation Oncology (MAASTRO), Radiation Oncology, 
Maastricht, The Netherlands  
 
Intensity-modulated radiotherapy (IMRT) has provided a means for 
shaping the dose distribution not only to the geometry but also to the 
differences in radiobiology across tumors. This information on tumor 
biology and heterogeneity can be derived from functional images. The 
spectrum of imaging biomarkers consists of imaging of tumor 
metabolism (PET with new tracers), angiogenesis (perfusion MRI), 
cellularity (diffusion MRI) and  hypoxia (FMISO PET and BOLD MRI)  
Apart from that, automated segmentation of imaging data, provides 
per pixel measurement of the heterogenous characteristic of the 
tumor in a objective way and improves the assessment of response to 
radiation oncology by imaging.  
This lecture is to learn about the range of MR imaging biomarkers that 
can be used for markers of tumor microenvironment and 
heterogeneity and to understand how these biomarkers can assist 
IMRT in radiotherapy. 
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PRV margins and other measures to handle geometrical 
uncertainties of normal tissue 
L. Hysing1, B. Heijman2, L.P. Muren3 
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An important goal in radiotherapy is to minimize the risk of adverse 
side effects following treatment. Geometrical uncertainties make this 
a challenging task because they cause variation in the delivered 
normal tissue dose. A method/concept for handling geometrical 
uncertainties of normal tissue should ideally be able to 1) predict the 
delivered dose to the organ at risk (OAR) in question – within a certain 
probability, 2) allow for correlation of predicted dose-volume 
parameters with adverse effects to develop reliable complication-
/organ-specific constraints, and 3) communicate these constraints to 
the optimization algorithm. 
The ICRU report no.62 introduced the concept of a planning organ at 
risk volume (PRV) to address this problem – in analogy to the planning 
target volume (PTV) [1]. While the PTV should secure the prescribed 
dose to be delivered to the clinical target volume (CTV) with a certain 
probability, the PRV should help controlling normal tissue 
complications. The latter is more challenging both because the shape 
of the dose distribution around OARs is case dependent and will vary 
much more than for the CTV and because the dose-volume response 
varies from organ to organ [2-4]. Consequently, no universal PRV 
recipe – in analogy to the van Herk [5] or Stroom [6] recipes for PTVs – 
exists, and the concept of PRV is somewhat confusing. Inconsistency in 
the ICRU report no. 62 and 83 about for which organ and when to use 
PRVs further contributes to the uncertainty of the concept [1,7]. 
Despite no general PRV recipe – the concept is well established and 
plays an important role in clinical cases where a serial OAR is close to 
a critical dose level (e.g. around the spinal cord in head and neck 
IMRT) [2,3,8,9]. The usefulness of the PRV concept for other 
treatment situations and OARs with a less serial dose-volume response 
is debated [3,10].  
Patient-specific alternatives to PRVs have been suggested and are 
promising [11-16].Some of these concepts completely abandon the use 
of hard margins – both PRVs and PTVs and replace them by directly 
incorporating geometrical uncertainties of the CTVs and OARs in so-
called robust optimization. Implementing these concepts clinically 
would thus require us to reframe our thinking into a more abstract 
way of evaluating dose distributions. Nevertheless, these alternatives 
could help us to better exploit the potentials of advanced 
radiotherapy delivery techniques, including intensity-modulated 
photon and hadron therapy. 
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A practical guide to radiochromic film dosimetry 
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Historically the standard tool for quality assurance of IMRT has been 
radiographic film, which has had a long history of use in radiotherapy 
QA programs. The trend towards filmless radiology and radiotherapy 
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departments, however, will lead to essentially no access to traditional 
radiographic film and wet developer systems. An alternative is 
dosimetry without film processors using radiochromic films. Starting 
with the MD-55 (mainly used in brachytherapy) these polymere based 
dosimeters attracted attention in the radiotherapy community in the 
last decade. Some issues like low radiosensitivity, low homogeneity, 
small film size and time and temperature dependencies prevented a 
wide clinical use. Further developments lead to increased radio-
sensitivity and the three generations of EBT films, which are nowadays 
widely used in radiotherapy clinics. This teaching lecture will 
therefore focus specifically on radiochromic film dosimetry and its 
practical aspects for quality assurance purposes in radiotherapy. 
The advantage of radiochromic film dosimetry is that they don´t need 
chemical or physical processing and are self-developing. In addition 
the composition of the film is nearly tissue equivalent. The grainless 
appearance offers a very high resolution (to 5um) and further 
advantages are its dose rate independency, good energy 
characteristics and consequently no strong energy dependence at low 
photon energies as well as a wide dynamic range from cGy to >40 Gy. 
Despite their superior characteristics compared to e.g. radiographic 
films still influencing variables do exist and neglecting those can lead 
to suboptimal results. During the teaching lecture pitfalls in handling 
and parameters of influence on the read out signal are pin pointed. 
Few examples are scanning orientation, post-irradiation darkening and 
UV sensitivity. A new generation of EBT films (EBT 3) are currently 
available and the changes related to the new design are specifically 
addressed.   
The characteristics of EBT films define their application as QA tool in 
highly conformal and complex treatment strategies like IMRT, VMAT or 
proton therapy. The teaching lecture is tailored to those who want to 
set up a radiochromic film dosimetry protocol. Questions, which will 
be discussed, are for example – What are the essentials I need? How 
should I handle the film? What do I need to know about scanning? 
Which scanner should I use? What colour channel should I use? What is 
the difference between EBT2 and EBT3? How can I get rid of 
uniformity issues of the film and the scanner? How to deal with 
Newton´s ring artifacts? What is the achievable accuracy with 
radiochromic films?  
 
SP-0197   
Delineation of normal stuctures: Where we are and what we are 
aiming for 
M.A. Gambacorta1 
1Università Cattolica del Sacro Cuore, Radiotherapy Department, 
Rome, Italy  
  
In the 3D-era the organs at risk (OARs) were contoured and evaluated 
by the Radiation Oncologist (RO) with the aim to report the dose 
delivered to the normal  structures, without any significant impact on 
the calculation of dose distribution on treatment plan. The 
implementation of diagnostic imaging and TPS imaging management 
tools brought to a better definition of OARs. Moreover, the 
introduction of new techniques  of radiation delivery, such as IMRT, 
and the possibility to register during the treatment the accumulated 
dose, is challenging both for RO and RTT. However this 
implementation of thetechnology led to an increased time for 
delineation. Although the TPS in use in the majority of the Radiation 
Centers in the world have already the possibility to automatically 
delineate the OARs with an intrinsic high resolution contrast (bones 
and lungs) with a good reliability and a significant time sparing, the 
delineation of the other OARs is still manual. Moreover, due to the 
even more importance of OARs in the treatment definition, an 
Independent Check (IC) should be warranted. The possibility given by 
IMRT to sculpture the dose around the target yielded to a greater 
attention to OARs in all the phases of treatment:  
1.    Prescription 
2.    Delineation 
3.    Dose calculation 
4.    Evaluationof TP  
5.    Verificationduring treatment 
1. Prescription: the RO has the possibility to prescribe the dose both 
to the target and to OARs. 
2. Delineation: a growing number of structures have to be manually 
delineated by the RTT to account for toxicities in irradiated healthy 
organs (swallowing muscles in head and neck, bladder trigone in the 
pelvis,brachial plexus in axillary lymph nodes irradiation…). Many are 
drawbacks of this procedure: it is time consuming, it is not well 
standardized, indeed there are not international published ATLAS to 
guide in the delineation: for H&N cancer, just institutional 
experiences (Christianen ME et al, RO 2011, van deWater TA et al, RO 
2009), whereas for the delineation of OARs in pelvicsites a RTOG atlas 
has recently been published  (Gay HA et al, IJROBP 2012), finally 
there isnot an IC procedures. 
3. Dose calculation for IMRT plan requests the definition of dose 
constraints both on PTVs and OARs 
4. Evaluation of TP: in the evaluation of thetreatment planning the RO 
has to evaluate the distribution of dose not only in the target 
volumes, but also in the OARs, with the possibility to modify the TP in 
order to respect the constraints. 
5. Verification during treatment: it is known that during RT there are 
modifications of the distribution of dose both in target volumes and in 
OARs due to shrinkage of the tumor and OAR, and/or body 
modification for toxicities. Therefore it is important the replanning 
time where a new PT is created based on the new anatomy of the 
patients. This procedure, although guarantees a better precision in 
the calculation of the delivered dose it is time consuming. 
Where new technologies can help in such complex procedures?  
The development of new softwares brought to the scenario of RO and 
RTT tools for auto-delineation and for the auto-replanning of target 
volumes and OARs, these softwares, which still need of clinical 
validation and should be always followed by IC, could bring to a 
significant time savings, which could finally allow to increase the 
number of patients treated and to the number of checks during the 
treatment. 
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Effect of high doses per fraction  
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1Medizinische Universität Wien, Dept. of Radiation Oncology 
&Christian Doppler Laboratory for Medical Radiation Research in 
Radiooncology, Vienna, Austria  
 
Doses per fraction larger than the conventional 2 Gy are applied in 
curative intent e.g.in moderate hypofractionation strategies (2.5 
Gy/fraction), in highly conformal external beam irradiation protocols, 
such as stereotactic or hadron therapies, and in brachytherapy. These 
regimen, however, usually do not only differ in the size of the dose 
per fraction, but also with regard to overall treatment time and total 
dose. Moreover, large doses per fraction are usually administered to 
(normal tissue) volumes that are clearly smaller than in conventional 
protocols. All these parameters need to be included into 
considerations concerning the biological effect of large dose per 
fraction protocols - independently for tumor, early and late 
responding tissues. The effect of dose per fraction (“recovery”) for 
tumors was historically - with few exceptions (e. g. melanoma and 
liposarcoma) - considered as low, as expressed by a high α/β-value in 
the linear-quadratic (LQ-)model. Recently, a high fractionation effect 
was shown for prostate and breast tumors, and is currently discussed 
for others. Early responding normal tissues usually show a low 
fractionation effect, while most late radiation effects display a high 
sensitivity for dose per fraction. Hence, doses per fraction must be 
adjusted to the respective tumor type as well as the organs at risk and 
the (late) morbidity pattern in order to achieve the biologically 
equieffective doses that result in optimum dissociation between 
treatment efficacy and adverse events. It was postulated that the LQ-
model may not be applicable for large doses per fraction (>6-10 Gy), 
as indicated by in-vitro cell survival data. However, in most pre-
clinical analyses of the fractionation effect large doses per fraction 
were included, but without a major deviation of the resulting α/β-
values from the respective estimates from clinical data, which barely 
supports the conclusions from the in-vitro studies. If at all, then the 
linear-quadratic model overestimates the effects of exposure to high 
doses per fraction. Most curative therapy protocols with high doses 
per fraction are associated with a shortened overall treatment time. 
This may also contribute to increased tumor effectiveness of the 
treatment. However, it also is less permissive for regenerative 
processes (“repopulation”) in normal tissues. These protocols 
therefore include a risk of increased early normal tissue reactions and 
thus, in certain tissues, also of enhanced (“consequential”) late 
effects. The administration of large doses per fraction to normal 
tissues, particularly in stereotactic treatment approaches, is mainly 
facilitated by a high conformality of the high-dose volume to the 
target volume, and steep dose gradients in normal tissues. However, 
it must be emphasized that very high doses per fraction may not only 
change the quantity of normal tissue changes, but may also clearly 
alter tissue pathophysiology and thus result in morbidity endpoints 
that are usually not observed with conventional or moderately 
hypofractionated protocols. Prominent examples are the 
manifestation of atrophic rather than fibrotic processes, e. g. after 
brachytherapy, or the occurrence of pathological rib fractures after 
stereotactic radiotherapy of peripheral lung tumors. In conclusion, 
administration of large doses per fraction may be advantageous for 
biological, but also for economic reasons. However, such approaches 
not only impact on tissue recovery, but can also affect other 
radiobiological parameters (radiopathology, repopulation, volume 
effects) in a highly complex manner. Therefore, the patients included 
